Theratechnologies Brief: Says Received March 2025 PDUFA Goal Date For Updated Tesamorelin F8 Formulation SBLA

MT NewswiresDec 10 15:15 ET

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation SBLA

GlobeNewswireDec 10 15:15 ET

Theratechnologies Gets Medical Review Committee Approval for Higher Doses of TH1902 at Phase 1b Trial

MT NewswiresDec 9 08:55 ET

Theratechnologies Announces Preliminary Tolerability, Efficiacy Data for TH1902

TipRanksDec 9 08:47 ET

Theratechnologies Shows Promise in Ovarian Cancer Trial

TipRanksDec 9 08:14 ET

Theratechnologies Brief: Announcing Preliminary Tolerability and Efficacy Data From Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients With Advanced Ovarian Cancer

MT NewswiresDec 9 07:32 ET